RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,104,125 | -6.7% | 144,330 | -8.9% | 0.00% | 0.0% |
| Q2 2023 | $1,183,188 | +79.7% | 158,392 | +60.5% | 0.00% | +100.0% |
| Q1 2023 | $658,289 | -12.5% | 98,694 | +1.1% | 0.00% | 0.0% |
| Q4 2022 | $752,434 | -26.5% | 97,592 | +1.4% | 0.00% | -50.0% |
| Q3 2022 | $1,024,000 | +27.7% | 96,266 | -2.3% | 0.00% | +100.0% |
| Q2 2022 | $802,000 | +32.8% | 98,520 | +16.7% | 0.00% | 0.0% |
| Q1 2022 | $604,000 | -63.4% | 84,397 | -12.4% | 0.00% | -50.0% |
| Q4 2021 | $1,650,000 | +371.4% | 96,335 | +533.7% | 0.00% | – |
| Q3 2021 | $350,000 | -67.1% | 15,203 | -47.9% | 0.00% | -100.0% |
| Q2 2021 | $1,064,000 | – | 29,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |